lunes, 3 de noviembre de 2014

JCO Exclusive: Predicting Response to Anti-HER2 Treatments: Is HER2 the Only Biomarker? | ASCO Connection

JCO Exclusive: Predicting Response to Anti-HER2 Treatments: Is HER2 the Only Biomarker? | ASCO Connection

ASCO Connection – professional networking for ASCO’s worldwide oncology community

JCO Exclusive: Predicting Response to Anti-HER2 Treatments: Is HER2 the Only Biomarker?

Online Exclusives

27 Oct 2014 6:58 PM
    
  
    Key Points

  • This study found that HER2 remains the only biomarker that can be used to select which women have a high chance of responding to anti-HER2 treatments.
  • Women who received pertuzumab had better outcomes compared with women who received a placebo, regardless of the types of biomarkers each patient carried, as long as the tumors were HER2-positive. However, certain biomarkers were associated with better or worse outcomes.
  • Of all the biomarkers, PIK3CA had the greatest effect on outcome: women with mutated PIK3CA had a significantly lower PFS than women with wild-type. This finding is a compelling reason to carry out studies of PIK3CA-inhibitors.
  
       
By Shira Klapper, Senior Writer/Editor
For the past 15 years, anti-HER2 treatments have been used to treat women with HER2-positive breast cancer. In all that time, the HER2 biomarker has remained the sole biomarker used to predict whether patients will be sensitive to anti-HER2 treatments, which are comprised of monoclonal antibodies that work by binding to HER2 and inducing the cell’s death.
Now, a new study published in the Journal of Clinical Oncology (JCO), published online, ahead of print, October 13, asks—are there additional biomarkers, independent of HER2, that can help to identify who might benefit from anti-HER2 monoclonal antibodies, specifically the combination of pertuzumab plus trastuzumab?

No hay comentarios:

Publicar un comentario